Adaptive approach to trial design and operation is key, Health Decisions

By Gareth Macdonald

- Last updated on GMT

Related tags: Clinical trial

An adaptive approach to both the design and operation of a clinical trial can boost efficiency, reduce timelines and cut costs says Health Decisions' CEO Michael Rosenberg.

Rosenberg spoke with Outsourcing-pharma at DIA Euro Meeting in Monaco and explained that although adaptive clinical trial design is a well established practice, CROs and drugmakers have only "scraped the surface​" in the use of an adaptive approach to trial operations.

He highlighted enrollment as one operational area that could be improved explaining that Health Decisions' research indicates that 76 per cent of adaptive trials meet enrollment timelines compared with just 15 per cent of traditional studies.

The other advantage of an adaptive approach to trial operations is that, unlike adaptive changes at the design level, they do not require regulatory approval and thus give CROs and sponsors direct control over some of the most costly and time consuming aspects of a clinical study.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more


View more